5-fluorouracil + folinic acid + mitoxantrone + prednisone

This is a combination chemotherapy regimen consisting of four drugs: - **5-fluorouracil** (5-FU): an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death, primarily in rapidly dividing cancer cells. - **Folinic acid** (leucovorin): a reduced form of folic acid that enhances the binding of 5-FU to thymidylate synthase, increasing its cytotoxic effect. Folinic acid itself is not cytotoxic but potentiates the action of 5-FU[2][3]. - **Mitoxantrone**: an anthracenedione antineoplastic agent that intercalates into DNA and inhibits topoisomerase II, resulting in inhibition of DNA replication and repair. It also has immunosuppressive properties[8]. - **Prednisone**: a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive effects; it is commonly used as part of palliative regimens for hormone-refractory prostate cancer when combined with mitoxantrone[8]. This specific four-drug combination does not have a widely recognized brand or protocol name but represents an intensive multi-agent chemotherapy approach potentially used for advanced cancers such as metastatic prostate cancer or other solid tumors where each component has demonstrated efficacy either alone or in smaller combinations.